InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,464.62
(
-0.16%
)
US TECH 100
19,185.60
(
-0.11%
)
Dow Jones
39,150.33
(
0.04%
)
Brent Oil
84.89
(
1.03%
)
Bitcoin
61,135.72
(
-3.20%
)
Post# of 252311
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 833
Posts 119895
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: oc631 post# 156685

Friday, 02/08/2013 3:10:59 PM

Friday, February 08, 2013 3:10:59 PM

Post# of 252311

GILD/ABBV/BMY/etc—The bind now is very few classes of HCV drugs work in GT3 outside of nukes. The greatest progress looks to be in the NS5A class with work to be done. GILD mentioned they are working on a second pre-clinical nuke…

Have you completely discounted the possibility that extending treatment from 12w to 16w will make a material difference in the FUSION study? (You did not reply to #msg-84224590.) I think it’s unlikely, but not hopeless.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up